Long‐term outcome of expanded newborn screening at Boston children's hospital: benefits and challenges in defining true disease
Authors:
- 4 January 2017
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 40 (2) , 209-218
Abstract
Introduction: There is no universal consensus of the disorders included in newborn screening programs. Few studies so far, mostly short‐term, have compared the outcome of disorders detected by expanded newborn screening (ENBS) to the outcome of the same disorders detected clinically.Methods: We compared the clinical and neurodevelopmental outcomes in patients with metabolic disorders detected by ENBS, including biotinidase testing, with those detected clinically and followed at the Metabolism Clinic at Boston Children's Hospital.Results: One hundred eighty‐nine patients came to attention from ENBS and 142 were clinically diagnosed. 3‐methylcrotonyl‐CoA carboxylase, biotinidase, and carnitine deficiencies were exclusively identified by ENBS and medium chain acyl‐CoA dehydrogenase (MCADD) and very long chain acyl‐CoA dehydrogenase deficiencies (VLCADD) were predominantly identified by ENBS whereas the organic acid disorders more often came to attention clinically. Only 2% of the ENBS‐detected cases had clinically severe outcomes compared to 42% of those clinically detected. The mean IQ score was 103 + 17 for the ENBS‐detected cases and 77 + 24 for those clinically detected. Those newly included disorders that seem to derive the greatest benefit from ENBS include the fatty acid oxidation disorders, profound biotinidase deficiency, tyrosinemia type 1, and perhaps carnitine deficiency.Conclusion: Although the NBS‐identified and clinically‐identified cohorts were not completely comparable, this long‐term study shows likely substantial improvement overall in the outcome of these metabolic disorders in the NBS infants. Infants with mild disorders and benign variants may represent a significant number of infants identified by ENBS. The future challenge will be to unequivocally differentiate the disorders most benefitting from ENBS and adjust programs accordingly.Keywords
This publication has 49 references indexed in Scilit:
- Efficacy and outcome of expanded newborn screening for metabolic diseases - Report of 10 years from South-West Germany *Orphanet Journal of Rare Diseases, 2011
- Mitochondrial fatty acid oxidation disorders: clinical presentation of long‐chain fatty acid oxidation defects before and after newborn screeningJournal of Inherited Metabolic Disease, 2010
- Lack of genotype–phenotype correlations and outcome in MCAD deficiency diagnosed by newborn screening in New York StateMolecular Genetics and Metabolism, 2010
- The consequences of extended newborn screening programmes: Do we know who needs treatment?Journal of Inherited Metabolic Disease, 2008
- Disorders of carnitine transport and the carnitine cycleAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2006
- ‘Classical’ organic acidurias, propionic aciduria, methylmalonic aciduria and isovaleric aciduria: Long‐term outcome and effects of expanded newborn screening using tandem mass spectrometryJournal of Inherited Metabolic Disease, 2006
- Newborn screening for biotinidase deficiency: pilot study and follow-up of identified casesScreening, 1992
- The origin of newborn screeningScreening, 1992
- Deficient Biotinidase Activity in Late-Onset Multiple Carboxylase DeficiencyNew England Journal of Medicine, 1983
- Intellectual development in patients with untreated histidinemia: A collaborative study group of neonatal screening for inborn errors of metabolism in JapanThe Journal of Pediatrics, 1982